Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Air pollution, noise and hypertension : Partners in crime].

Herz·2024
Same author

Etiologies and predictors of mortality in an all-comer population of patients with non-ischemic heart failure.

Clinical research in cardiology : official journal of the German Cardiac Society·2024
Same author

[Utilization of video consultation in cardiovascular lipid treatment].

Herz·2023
Same author

Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.

Thrombosis research·2023
Same author

Reducing the health impacts of ambient air pollution.

BMJ (Clinical research ed.)·2022
Same author

The association of depression and all-cause mortality: Explanatory factors and the influence of gender.

Journal of affective disorders·2022
Same journal

Update: Immune Tolerance Induction Practice in Haemophilia.

Hamostaseologie·2026
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Apixaban].

S Konstantinides1, T Münzel

  • 1Centrum für Thrombose und Hämostase, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany. stavros.konstantinides@unimedizin-mainz.de

Hamostaseologie
|June 29, 2012
PubMed
Summary
This summary is machine-generated.

Apixaban, a factor Xa inhibitor, offers effective stroke and venous thromboembolism prevention. Clinical trials show superiority over warfarin and aspirin in specific patient groups, highlighting its therapeutic value.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Hematology

Context:

  • Apixaban is a novel oral anticoagulant targeting activated factor X.
  • It possesses favorable pharmacokinetic and pharmacodynamic properties, including good bioavailability and minimal drug interactions.
  • The drug has undergone extensive Phase 3 clinical trials for various indications.

Purpose:

  • To evaluate the efficacy and safety of apixaban in preventing stroke and venous thromboembolism.
  • To compare apixaban with existing treatments like warfarin and aspirin.
  • To assess apixaban's role in post-operative prophylaxis and treatment of thrombotic events.

Summary:

  • Apixaban demonstrated superior stroke prevention and reduced major bleeding compared to warfarin in atrial fibrillation patients (ARISTOTLE).
  • It proved more effective than aspirin for stroke prevention in atrial fibrillation (AVERROES).
  • Apixaban is approved for venous thromboembolism prophylaxis post-orthopedic surgery (ADVANCE), with ongoing studies for treatment and extended prophylaxis (AMPLIFY/AMPLIFY-EXT).

Impact:

  • Apixaban presents a valuable therapeutic option for preventing venous thrombosis and embolic stroke.
  • Trial results indicate a balanced efficacy and safety profile across different indications.
  • Negative results in specific patient populations (e.g., hospitalized medical patients, acute coronary syndrome) define its current limitations.